Literature DB >> 4453421

The perceived effects of marijuana on spinal cord injured males.

M Dunn, R Davis.   

Abstract

Entities:  

Mesh：

Year:  1974        PMID： 4453421     DOI： 10.1038/sc.1974.28

Source DB:  PubMed          Journal:  Paraplegia        ISSN： 0031-1758


× No keyword cloud information.
  8 in total

1.  Treatments for chronic pain in persons with spinal cord injury: A survey study.

Authors:  Diana D Cardenas; Mark P Jensen
Journal:  J Spinal Cord Med       Date:  2006       Impact factor: 1.985

Review 2.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

3.  Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial.

Authors:  M Maurer; V Henn; A Dittrich; A Hofmann
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1990       Impact factor: 5.270

Review 4.  Analyzing the Impact of Cannabinoids on the Treatment of Spinal Disorders.

Authors:  Rohan M Shah; Anjay Saklecha; Alpesh A Patel; Srikanth N Divi
Journal:  Curr Rev Musculoskelet Med       Date:  2022-02-08

5.  Characteristics of Individuals with Spinal Cord Injury Who Use Cannabis for Therapeutic Purposes.

Authors:  Claudia Drossel; Martin Forchheimer; Michelle A Meade
Journal:  Top Spinal Cord Inj Rehabil       Date:  2016

6.  Effect of cannabinoids on spasticity and ataxia in multiple sclerosis.

Authors:  H M Meinck; P W Schönle; B Conrad
Journal:  J Neurol       Date:  1989-02       Impact factor: 4.849

Review 7.  [Therapeutic use of cannabinoids in neurology].

Authors:  P Schwenkreis; M Tegenthoff
Journal:  Schmerz       Date:  2003-10       Impact factor: 1.107

8.  The Therapeutic Potential and Usage Patterns of Cannabinoids in People with Spinal Cord Injuries: A Systematic Review.

Authors:  Kylie J Nabata; Emmanuel K Tse; Tom E Nightingale; Amanda H X Lee; Janice J Eng; Matthew Querée; Matthias Walter; Andrei V Krassioukov
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.